JP2020519284A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519284A5
JP2020519284A5 JP2019562332A JP2019562332A JP2020519284A5 JP 2020519284 A5 JP2020519284 A5 JP 2020519284A5 JP 2019562332 A JP2019562332 A JP 2019562332A JP 2019562332 A JP2019562332 A JP 2019562332A JP 2020519284 A5 JP2020519284 A5 JP 2020519284A5
Authority
JP
Japan
Prior art keywords
grna
nucleic acid
seq
protein
itr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019562332A
Other languages
English (en)
Other versions
JP7327803B2 (ja
JP2020519284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031880 external-priority patent/WO2018208972A1/en
Publication of JP2020519284A publication Critical patent/JP2020519284A/ja
Publication of JP2020519284A5 publication Critical patent/JP2020519284A5/ja
Application granted granted Critical
Publication of JP7327803B2 publication Critical patent/JP7327803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (25)

  1. アデノ随伴ウイルス(AAV)逆位末端リピート(ITR)に隣接する、C9ORF72遺伝子のGリピートの反対側に隣接する標的核酸配列に対して特異的にハイブリダイズする2以上のガイドRNA(gRNA)をコードする導入遺伝子を含む、単離された核酸。
  2. 2以上のgRNAが、各々、配列番号1〜4のいずれか1つに示される配列、またはそれらのいずれか1つに相補的な配列を含むまたはからなる、請求項1に記載の単離された核酸。
  3. 導入遺伝子が、配列番号1に示される配列を有する第1のgRNAおよび配列番号3に示される配列を有する第2のgRNAをコードする、請求項1または2に記載の単離された核酸。
  4. 導入遺伝子が、配列番号2に示される配列を有する第1のgRNAおよび配列番号3に示される配列を有する第2のgRNAをコードする、請求項1または2に記載の単離された核酸。
  5. AAV ITRが、AAV2 ITR、AAV3 ITR、AAV4 ITR、AAV5 ITR、AAV6 ITR、AAV7 ITR、AAV8 ITR、またはAAV9 ITRである、請求項1〜4のいずれか一項に記載の単離された核酸。
  6. 導入遺伝子がプロモーターを含み、任意に、プロモーターがCBプロモーターである、請求項1〜5のいずれか一項に記載の単離された核酸。
  7. 配列番号1〜4のいずれか1つに示される配列、またはそれらのいずれか1つに相補的な配列を有するガイドRNA(gRNA)をコードする核酸配列を含む、単離された核酸。
  8. (i)請求項1〜7のいずれか一項に記載の単離された核酸;および
    (ii)少なくとも1のAAVカプシドタンパク質
    を含む、組み換えアデノ随伴ウイルス(rAAV)。
  9. カプシドタンパク質が、AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、または上記のいずれかのバリアントから選択される血清型のものである、請求項8に記載のrAAV。
  10. カプシドタンパク質が、AAV9カプシドタンパク質である、請求項8または9に記載のrAAV。
  11. 請求項8〜10のいずれか一項に記載のrAAV、および組み換え遺伝子編集タンパク質を含む、組成物。
  12. 組み換え遺伝子編集タンパク質が、rAAVベクターによってコードされる、請求項11に記載の組成物。
  13. 組み換え遺伝子編集タンパク質が、CRISPR/Casタンパク質であり、任意に、Cas9タンパク質である、請求項11または12に記載の組成物。
  14. (i)C9ORF72遺伝子のGリピートの反対側に隣接する標的核酸配列に対して特異的にハイブリダイズする2以上のガイドRNA(gRNA);および
    (ii)2以上のgRNAと相互作用する組み換え遺伝子編集タンパク質
    を発現する、哺乳動物の細胞。
  15. 組み換え遺伝子編集タンパク質がCRISPR/Casタンパク質である、請求項14に記載の哺乳動物の細胞。
  16. 組み換え遺伝子編集タンパク質が、Cas9、Cas6、およびCpf1から選択されるCasタンパク質である、請求項14または15に記載の哺乳動物の細胞。
  17. gRNAの各々が、配列番号1〜4のいずれか1つに示される配列、またはそれらのいずれか1つに相補的な配列を含む、請求項14〜16のいずれか一項に記載の哺乳動物の細胞。
  18. 細胞が、C9ORF72遺伝子のGリピートの反対側に隣接する標的核酸配列に対して特異的に各々ハイブリダイズする、2、3、または4のgRNAを発現する、請求項14〜17のいずれか一項に記載の哺乳動物の細胞。
  19. 配列番号1に示される配列を有する第1のgRNAおよび配列番号3に示される配列を有する第2のgRNAを発現する、請求項14〜18のいずれか一項に記載の哺乳動物の細胞。
  20. 配列番号2に示される配列を有する第1のgRNAおよび配列番号3に示される配列を有する第2のgRNAを発現する、請求項14〜18のいずれか一項に記載の哺乳動物の細胞。
  21. (i)組み換え遺伝子編集タンパク質;および
    (ii)C9ORF72遺伝子のGリピートの反対側に隣接する標的核酸配列に対して特異的にハイブリダイズする2以上のガイドRNA(gRNA)
    を細胞へ送達することを含む、方法。
  22. gRNAが、配列番号1〜4から選択される配列またはそれらのいずれか1つに相補的な配列を含む、請求項21に記載の方法または複合体。
  23. (i)C9ORF72遺伝子のエキソン領域に対して特異的にハイブリダイズするガイドRNA(gRNA);および
    (ii)gRNAと相互作用する組み換え遺伝子編集タンパク質
    を発現する、哺乳動物の細胞。
  24. 細胞においてC9ORF72遺伝子のエキソン領域に対して特異的にハイブリダイズするガイドRNA(gRNA)およびgRNAと相互作用する組み換え遺伝子編集タンパク質を含む組み換え遺伝子編集複合体を発現させることを含む、細胞においてRNAフォーカスおよび/またはジペプチド形成を低減する方法であって、
    組み換え遺伝子編集複合体の細胞への送達が、前記遺伝子から転写されたC9orf72転写産物のナンセンス変異依存分解につながるC9ORF72遺伝子における挿入または欠失をもたらす、前記方法。
  25. (i)C9ORF72遺伝子の1以上のエキソン領域に対して特異的にハイブリダイズするガイドRNA(gRNA);および
    (ii)gRNAと相互作用する組み換え遺伝子編集タンパク質
    を細胞へ送達することを含む、方法。
JP2019562332A 2017-05-09 2018-05-09 筋萎縮性側索硬化症(als)を処置する方法 Active JP7327803B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762503909P 2017-05-09 2017-05-09
US62/503,909 2017-05-09
PCT/US2018/031880 WO2018208972A1 (en) 2017-05-09 2018-05-09 Methods of treating amyotrophic lateral sclerosis (als)

Publications (3)

Publication Number Publication Date
JP2020519284A JP2020519284A (ja) 2020-07-02
JP2020519284A5 true JP2020519284A5 (ja) 2021-07-26
JP7327803B2 JP7327803B2 (ja) 2023-08-16

Family

ID=64104908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562332A Active JP7327803B2 (ja) 2017-05-09 2018-05-09 筋萎縮性側索硬化症(als)を処置する方法

Country Status (6)

Country Link
US (2) US11859179B2 (ja)
EP (1) EP3622073A4 (ja)
JP (1) JP7327803B2 (ja)
AU (1) AU2018264996A1 (ja)
CA (1) CA3059213A1 (ja)
WO (1) WO2018208972A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3750907A3 (en) 2014-03-18 2021-04-28 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
AU2016270587B2 (en) 2015-05-29 2020-12-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a disruption in a C9ORF72 locus
JP7026678B2 (ja) 2016-09-30 2022-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物
CN118006607A (zh) 2017-09-22 2024-05-10 马萨诸塞大学 Sod1双表达载体及其用途
JP7449291B2 (ja) 2018-12-20 2024-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヌクレアーゼ媒介リピート伸長
CA3172178A1 (en) * 2020-03-18 2021-09-23 Benjamin OAKES Compositions and methods for the targeting of c9orf72
GB202105455D0 (en) * 2021-04-16 2021-06-02 Ucl Business Ltd Composition
WO2023025103A1 (en) * 2021-08-22 2023-03-02 Huigene Therapeutics Co., Ltd. Crispr-cas13 system for treating sod1-associated diseases
WO2023086389A1 (en) * 2021-11-09 2023-05-19 Prime Medicine, Inc. Genome editing compositions and methods for treatment of amyotrophic lateral sclerosis

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6177403B1 (en) 1996-10-21 2001-01-23 The Trustees Of The University Of Pennsylvania Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4060531B2 (ja) 1998-05-28 2008-03-12 アメリカ合衆国 Aav5ベクターおよびその使用
US20030110526A1 (en) 1998-08-25 2003-06-12 Robert H. Brown Dysferlin mutations
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
WO2001029243A1 (en) 1999-10-15 2001-04-26 Dalhousie University Method and vector for producing and transferring trans-spliced peptides
US7638120B2 (en) 2000-03-14 2009-12-29 Thomas Jefferson University High transgene expression of a pseudotyped adeno-associated virus type
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
US6962815B2 (en) 2001-01-05 2005-11-08 Children's Hopital Inc. AAV2 vectors and methods
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
EP2270024B1 (en) 2001-06-21 2018-10-24 Ionis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
CA2452980A1 (en) 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
KR101021695B1 (ko) 2001-07-12 2011-03-15 유니버시티 오브 매사추세츠 유전자 불활성화를 매개하는 소형 간섭 rna의 생체내 제조
JP2004534543A (ja) 2001-07-13 2004-11-18 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン シュードタイプ化アデノ関連ウイルスおよびその使用
EP2338900B1 (en) 2001-11-13 2014-01-01 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof
PT2573170T (pt) 2001-12-17 2018-03-26 Univ Pennsylvania Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações
US20050137153A1 (en) 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
AU2003221733A1 (en) 2002-04-17 2003-11-03 University Of Florida Research Foundation, Inc. Improved raav vectors
US20070003518A1 (en) 2002-04-19 2007-01-04 Atkinson Mark A Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
ATE348153T1 (de) 2002-04-29 2007-01-15 Univ Pennsylvania Methode für die direkte gewinnung und amplifikation von integrierten viren aus zellulärer gewebe-dna
US20060093589A1 (en) 2004-02-19 2006-05-04 Warrington Kenneth H Vp2-modified raav vector compositions and uses therefor
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
AU2003261449A1 (en) 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン, インコーポレイテッド 機能的siRNAおよび超機能的siRNA
JP4966006B2 (ja) 2003-01-28 2012-07-04 セレクティス カスタムメイドメガヌクレアーゼおよびその使用
US20040219528A1 (en) 2003-04-15 2004-11-04 Morris David W. Novel therapeutic targets in cancer
US7387896B2 (en) 2003-03-26 2008-06-17 The Regents Of The University Of Michigan MicroRNA vectors
US20060228800A1 (en) 2003-05-15 2006-10-12 Shi-Lung Lin Novel Transgenic Methods Using intronic RNA
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
ES2712695T3 (es) 2003-06-02 2019-05-14 Univ Massachusetts Métodos y composiciones para controlar la eficacia de la silenciación del ARN
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
DK2292779T3 (en) 2003-09-30 2017-02-27 Univ Pennsylvania ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
KR101246862B1 (ko) 2004-03-05 2013-03-27 베니텍 리미티드 RNAi 제제의 동시 전달을 위한 다중 프로모터 발현카세트
US7498316B2 (en) 2004-04-06 2009-03-03 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using RNA interference
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
ES2385837T3 (es) 2004-12-15 2012-08-01 The University Of North Carolina At Chapel Hill Vectores quiméricos
US20060229268A1 (en) 2004-12-16 2006-10-12 Alsgen, Llc Small interference RNA (siRNA) molecules for modulating superoxide dismutase (SOD)
EP1877556B1 (en) 2005-03-25 2011-09-14 Medtronic, Inc. Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
ATE494372T1 (de) 2005-08-29 2011-01-15 Regulus Therapeutics Inc Verfahren für mir-122a-modulation
EP1979485A2 (en) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
EP1989308B1 (en) 2006-03-03 2017-05-31 ProMIS Neurosciences Inc. Methods and compositions to treat and detect misfolded-sod1 mediated diseases
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
EP2548438B1 (en) 2006-11-08 2015-08-05 Veritas Bio, LLC In vivo delivery of double stranded RNA to a target cell
WO2008125846A2 (en) 2007-04-12 2008-10-23 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
CA2687336C (en) 2007-05-23 2014-12-23 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
AU2008260103B2 (en) 2007-05-31 2014-04-03 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
WO2009079592A2 (en) 2007-12-17 2009-06-25 California Institute Of Technology Modulating immune system development and function through microrna mir-146
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
AU2009221064B2 (en) 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
WO2009146178A1 (en) 2008-04-15 2009-12-03 President And Fellows Of Harvard College Angiogenin and amyotrophic lateral sclerosis
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2009149182A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
EP2297185A1 (en) 2008-06-17 2011-03-23 Amsterdam Molecular Therapeutics (AMT) B.V. Parvoviral capsid with incorporated gly-ala repeat region
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
WO2010027446A2 (en) 2008-09-04 2010-03-11 Galenea Corp., Et Al. Synaptic vesicle cycling assays and systems
WO2010034314A1 (en) 2008-09-24 2010-04-01 Aarhus Universitet Retroviral delivery of synthectic gene cassettes
WO2010071454A1 (en) 2008-12-17 2010-06-24 Auckland Uniservices Limited Adeno-associated viral vectors and uses thereof
WO2010099383A2 (en) 2009-02-26 2010-09-02 The Johns Hopkins University Compositions and methods for ex vivo hepatic nucleic acid delivery
SG10202109219SA (en) 2009-05-02 2021-10-28 Genzyme Corp Gene therapy for neurodegenerative disorders
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US20120270930A1 (en) 2009-10-29 2012-10-25 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods and compositions for dysferlin exon-skipping
JP5894535B2 (ja) 2009-11-09 2016-03-30 ジーンポッド セラピューティクス アーベーGenepod Therapeutics Ab invivoでのニューロン特異的な最適化された連続DOPA合成用の新規ウイルスベクター構築物
CA2781332C (en) 2009-11-19 2018-09-04 National University Corporation Okayama University System for increasing gene expression and vector comprising the system
EP2524037B1 (en) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
BR112012018899A2 (pt) 2010-01-28 2015-09-15 Philadelphia Children Hospital "método para purificar partículas de vetor de vírus adeno-associado."
EP2542247A4 (en) 2010-03-01 2014-05-07 Philadelphia Children Hospital NUCLEIC ACID FOR ADDRESSING MULTIPLE REGIONS OF THE HCV GENOM
CA2833912C (en) 2010-04-23 2021-09-21 University Of Massachusetts Aav-based treatment of cholesterol-related disorders
CA3050894C (en) 2010-04-23 2022-10-18 University Of Massachusetts Multicistronic expression constructs
JP5963743B2 (ja) 2010-04-23 2016-08-03 ユニバーシティ オブ マサチューセッツ Cnsターゲティングaavベクターおよびその使用方法
US8906607B2 (en) 2010-04-30 2014-12-09 Cellectis Method for modulating double-strand break-induced homologous recombination
US8785413B2 (en) 2010-09-27 2014-07-22 Florida Atlantic University Research Corporation Materials and methods for the treatment of pathological neovascularization in the eye
WO2012109667A1 (en) 2011-02-12 2012-08-16 University Of Iowa Research Foundation Therapeutic compounds
WO2012142434A2 (en) 2011-04-15 2012-10-18 THE UNITED STATES OF AMERICA, as represented by the secretary, Depart.of Healtth and Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
EP2699680B1 (en) 2011-04-21 2017-12-27 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
EP3202914B2 (en) * 2011-08-31 2023-06-28 The University of Manchester Method for treating a neurodegenerative disease
AU2012322788B2 (en) 2011-10-11 2018-01-04 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
US20130142861A1 (en) 2011-12-05 2013-06-06 National Yang Ming University Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis
CN104520428B (zh) 2012-02-17 2018-09-21 费城儿童医院 将基因转移到细胞、器官和组织的aav载体组合物和方法
JP6385920B2 (ja) 2012-05-09 2018-09-05 オレゴン ヘルス アンド サイエンス ユニバーシティー アデノ随伴ウイルスプラスミド及びベクター
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
RU2730677C2 (ru) 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
AU2014205134B2 (en) 2013-01-14 2020-01-16 Recombinetics, Inc. Hornless livestock
WO2014114303A1 (en) 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
AU2014244167A1 (en) 2013-03-13 2015-10-08 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
AU2014227766B2 (en) 2013-03-15 2018-10-04 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV vectors
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
US10006049B2 (en) 2013-05-16 2018-06-26 University Of Florida Research Foundation, Incorporated Hairpin mRNA elements and methods for the regulation of protein translation
KR20230136697A (ko) 2013-06-05 2023-09-26 듀크 유니버시티 Rna-가이드 유전자 편집 및 유전자 조절
CN113425857A (zh) 2013-06-17 2021-09-24 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
US10155794B2 (en) 2013-07-16 2018-12-18 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to CEP290
JP6827320B2 (ja) 2013-08-05 2021-02-10 アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム LCA−8及び進行性RPを治療するための組換えAAV−Crumbsホモログ組成物及び方法
EP4219727A3 (en) 2013-08-27 2023-09-06 Research Institute at Nationwide Children's Hospital Products and methods for treatment of amyotrophic lateral sclerosis
MY192689A (en) 2013-10-11 2022-09-01 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
WO2015057727A1 (en) 2013-10-14 2015-04-23 Isis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
CA2932436A1 (en) * 2013-12-12 2015-06-18 The Broad Institute, Inc. Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
GB201401707D0 (en) 2014-01-31 2014-03-19 Sec Dep For Health The Adeno-associated viral vectors
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
WO2015150922A2 (en) 2014-03-17 2015-10-08 The Hospital For Sick Children β-HEXOSAMINIDASE PROTEIN VARIANTS AND ASSOCIATED METHODS FOR TREATING GM2 GANGLIOSIDOSES
EP3750907A3 (en) 2014-03-18 2021-04-28 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
PT3137497T (pt) 2014-05-02 2021-07-12 Genzyme Corp Vetores de aav para terapia genética na retina e snc
CA2949437C (en) 2014-05-20 2023-08-15 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
WO2015187825A2 (en) 2014-06-03 2015-12-10 University Of Massachusetts Compositions and methods for modulating dysferlin expression
CA2952697A1 (en) 2014-06-16 2015-12-23 The Johns Hopkins University Compositions and methods for the expression of crispr guide rnas using the h1 promoter
BR112017001725A2 (pt) 2014-07-31 2018-02-14 Association Inst De Myologie tratamento de esclerose lateral amiotrófica
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
JP7023108B2 (ja) 2014-10-21 2022-02-21 ユニバーシティ オブ マサチューセッツ 組み換えaavバリアントおよびその使用
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016167780A1 (en) * 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016172155A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
EP3285780A4 (en) 2015-04-24 2018-12-19 University of Massachusetts Modified aav constructions and uses thereof
US11104897B2 (en) * 2015-04-27 2021-08-31 Genethon Compositions and methods for the treatment of nucleotide repeat expansion disorders
EP3288594B1 (en) * 2015-04-27 2022-06-29 The Trustees of The University of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
US10016514B2 (en) 2015-05-15 2018-07-10 New Hope Research Foundation Polynucleotides, vectors and methods for insertion and expression of transgenes
PL3298134T3 (pl) 2015-05-16 2023-09-18 Genzyme Corporation Edycja genów mutacji głęboko intronowych
US20180140810A1 (en) 2015-06-01 2018-05-24 University Of Massachusetts Catheter assemblies
US10758545B2 (en) * 2015-06-25 2020-09-01 University Of Southern California Methods to treat neurological diseases
WO2017019876A1 (en) 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
WO2017023724A1 (en) 2015-07-31 2017-02-09 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
EP3394260B1 (en) * 2015-12-23 2021-02-17 CRISPR Therapeutics AG Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
JP7026678B2 (ja) * 2016-09-30 2022-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド C9orf72座位中にヘキサヌクレオチドリピート伸長を有する非ヒト動物
CN118006607A (zh) 2017-09-22 2024-05-10 马萨诸塞大学 Sod1双表达载体及其用途

Similar Documents

Publication Publication Date Title
JP2020519284A5 (ja)
JP2020019772A5 (ja)
JP2022190081A5 (ja)
JP2017509632A5 (ja)
JP2019116492A5 (ja)
HRP20192141T1 (hr) Genska terapija za retinitis pigmentosa
JP2018522529A5 (ja)
JP2020522269A5 (ja)
JP2020114235A5 (ja)
JP2021106619A5 (ja)
JP2018108113A5 (ja)
JP2020500541A5 (ja)
IL292999A (en) Preparations and methods for the treatment of amyotrophic lateral sclerosis
JP2017535266A5 (ja)
RU2019124473A (ru) Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани
JP2017529395A5 (ja)
CA3158518A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
JP2018515102A (ja) スペーサーを含む核酸分子およびその使用の方法
JPWO2021053222A5 (ja)
JPWO2020214613A5 (ja)
JPWO2020214609A5 (ja)
JPWO2021067448A5 (ja)
JP2020519294A5 (ja)
JPWO2020168222A5 (ja)
JPWO2019165050A5 (ja)